SCHEMBL4075730

SCHEMBL4075730

O=C(O)CCCC(=O)N1CCN(Cc2cc3ccccc3o2)CC1

nearest known ligand 0.60

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
HTR2B P41595 11/20 0.60
HTR1A P08908 8/20 0.60
DRD2 P14416 8/20 0.56
DRD4 P21917 2/20 0.50
DRD3 P35462 2/20 0.50
CA2 P00918 1/20 0.50
CA9 Q16790 1/20 0.50
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
GRIN2B Q13224 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27782046 0.84 HTR2B (0.70) HTR2BHTR1ADRD2DRD4DRD3
SCHEMBL5692985 0.81 HTR2B (0.60) HTR2BHTR1ADRD2DRD4DRD3
SCHEMBL3599466 0.78 CA2 (0.73) HTR2BHTR1ACA2CA9
SCHEMBL4754279 0.76 HTR2B (1.00) HTR2BHTR1ADRD2MEN1KMT2A
SCHEMBL205808 0.74 MAPK1 (0.41) HTR2BHTR1ADRD2DRD4DRD3
SCHEMBL4084095 0.74 SIGMAR1 (0.52) HTR1ADRD2DRD4DRD3
SCHEMBL23804835 0.74 CYP1A2 (0.51) HTR2BDRD2CA9MEN1KMT2A
SCHEMBL2979920 0.74 HTR2B (0.74) HTR2BHTR1ADRD2MEN1KMT2A
SCHEMBL6649681 0.73 HTR2B (0.73) HTR2BHTR1ADRD2
SCHEMBL6525112 0.73 HTR2B (0.73) HTR2BHTR1ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP claimed
JP-2007536323-A 2007-12-13 JP claimed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
EP-1745010-A1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2007-01-24 EP claimed
WO-2005110974-A1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2005-11-24 WO claimed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP disclosed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed
EP-1745010-A1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2007-01-24 EP disclosed
WO-2005110974-A1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds PKD1, DDC, DPYD HTR2B 1205/4885HTR1A 398/4885DRD2 2201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.